Metabolic Health
GLP-1 and Inflammation
Semaglutide measurably lowers a key inflammation marker in trial data, independent of how much weight is lost. Here is w...
Prediabetes is one of the few conditions in this area that is genuinely reversible. Established type 2 diabetes can be managed and sometimes put into remission, but prediabetes can be turned around outright.
That window matters, and in Pakistan it opens earlier than most people expect.
What prediabetes is
Blood sugar higher than normal but not yet in the diabetic range.
It means insulin resistance has developed and your pancreas is compensating by producing more insulin. For a period that works. Blood sugar stays roughly controlled while insulin levels climb.
Eventually the pancreas cannot keep pace, and blood sugar rises into the diabetic range.
The compensating phase is where intervention works. Insulin-producing cells are still functioning. Once enough of them are lost, the change becomes considerably harder to reverse.
Prediabetes usually causes no symptoms, which is why it is often found incidentally or not at all.
Why South Asians are at higher risk
This is not a minor difference and it changes the thresholds that apply to you.
Type 2 diabetes develops at lower BMI in South Asian populations than in Western populations.
It develops at younger ages.
The reason is body composition. At any given BMI, South Asians tend to carry proportionally more visceral fat, the metabolically active fat around the organs, and less subcutaneous fat. Visceral fat drives insulin resistance directly.
Some guidance uses lower BMI cut-offs for South Asian populations for exactly this reason, setting overweight and obesity thresholds below the standard 25 and 30.
The practical consequence is that a Pakistani adult at a BMI of 25, which looks unremarkable by standard charts, may already have significant insulin resistance. Calculate your BMI, then treat it as one input alongside waist measurement rather than the whole answer.
Waist circumference is arguably more informative here, because it reflects visceral fat directly.
What the evidence shows
The XENDOS trial, published in Diabetes Care, followed 3,305 people with obesity for four years, comparing orlistat plus lifestyle changes against placebo plus lifestyle changes.
Cumulative incidence of type 2 diabetes was 6.2 percent on orlistat against 9.0 percent on placebo, a relative risk reduction of 37.3 percent.
Notably, exploratory analysis found the preventive effect was explained by the difference in subjects who had impaired glucose tolerance at the start. In other words, the benefit concentrated in people who already had prediabetes.
Average weight loss was 5.8 kg against 3.0 kg, so a difference of under 3 kg produced a 37.3 percent reduction in diabetes progression in the at-risk group.
That ratio is the important part. A modest weight difference produced a large change in disease progression.
Why modest loss does so much
Insulin resistance responds disproportionately to weight reduction, particularly visceral fat reduction.
Visceral fat is metabolically active. It releases fatty acids directly into the portal circulation reaching the liver, and produces inflammatory signals that impair insulin action.
It also happens to be the fat that responds earliest to weight loss. So the first several kilograms lost tend to come disproportionately from the compartment that matters most metabolically.
That is why 5 to 7 percent reduction produces effects out of proportion to the number.
What to do about it
Get tested if you have risk factors. Family history, central obesity, PCOS, high blood pressure, raised triglycerides, or previous gestational diabetes. A fasting glucose and HbA1c are inexpensive and widely available.
Aim for 5 to 7 percent weight reduction. Roughly 4.5 to 6 kg on a 90 kg person. This is the range where the prevention evidence sits.
Reduce refined carbohydrate specifically. In Pakistan that means white rice, naan, roti quantity, sugary chai, bottled drinks and sweets. This is where most of the glycaemic load sits in typical diets.
Add protein and fibre, which flatten the post-meal glucose rise.
Walk after meals. Even ten to fifteen minutes measurably reduces the post-meal glucose peak, and it requires nothing but time.
Build muscle. Muscle is the main site of glucose disposal. Resistance training improves insulin sensitivity independently of weight change.
Fix sleep, since short sleep worsens insulin sensitivity directly.
Where medication fits
For people with prediabetes and obesity who cannot achieve or sustain weight loss through diet alone, medication is a legitimate consideration.
Metformin is used for diabetes prevention in some settings and is inexpensive and widely available in Pakistan. That is a decision for your doctor.
GLP-1 medication improves both weight and insulin sensitivity, though none is registered here.
A registered GLP-1 sublingual supplement works on appetite through the GLP-1 pathway with physician review before dispatch. METASLIM™ is not a pharmaceutical GLP-1 receptor agonist, does not treat diabetes, and should never replace prescribed glucose-lowering medication.
Its relevance to this article is narrower and honest. If the obstacle to achieving 5 to 7 percent reduction is appetite, appetite is what it addresses. Anyone with prediabetes should be managing it with a doctor who is monitoring their blood sugar.
Why this window matters
WHO's obesity fact sheet sets out how excess weight raises the risk of type 2 diabetes among other conditions.
Type 2 diabetes is not a mild diagnosis. It raises cardiovascular risk substantially and carries complications affecting kidneys, eyes, nerves and circulation over years.
Preventing it is considerably easier than treating it, and considerably cheaper. In a market where diabetes medication becomes a lifelong recurring cost, the arithmetic of prevention is compelling on its own.
Our guide to GLP-1 benefits beyond weight loss covers the wider evidence, and weight loss, blood pressure and cholesterol covers the related metabolic changes.
The summary
Prediabetes is genuinely reversible while insulin-producing cells are still compensating.
XENDOS found a 37.3 percent relative reduction in progression to type 2 diabetes over four years, concentrated in people who had impaired glucose tolerance at baseline.
The weight difference producing that was under 3 kg, because insulin resistance responds disproportionately to visceral fat reduction.
South Asians develop type 2 diabetes at lower BMI thresholds and younger ages, so standard charts understate risk here.
Waist measurement is arguably more informative than BMI for this purpose.
Walking after meals, reducing refined carbohydrate and building muscle all improve insulin sensitivity directly.
See if you qualify for the program if appetite is preventing you reaching 5 to 7 percent.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified physician before starting any weight loss program, medication, or supplement.